{"id":"bpa-prophylaxis","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL204944","moleculeType":"Small molecule","molecularWeight":"401.47"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BPA (breakthrough polyomavirus-associated nephropathy) is a serious complication in transplant recipients. This prophylactic approach aims to prevent polyomavirus replication and associated kidney disease in high-risk immunocompromised populations. The exact mechanism may involve viral suppression or immune reconstitution strategies.","oneSentence":"BPA prophylaxis prevents breakthrough polyomavirus-associated nephropathy (BPA) in immunocompromised patients, likely through antiviral or immunomodulatory mechanisms.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:43:05.939Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of breakthrough polyomavirus-associated nephropathy in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT07285460","phase":"PHASE3","title":"A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Years With Hemophilia A or B","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-12-18","conditions":"Hemophilia","enrollment":85},{"nctId":"NCT05662319","phase":"PHASE3","title":"A Study to Test a Medicine (Fitusiran) Injected Under the Skin for Preventing Bleeding Episodes in Male Adolescent or Adult Participants With Severe Hemophilia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2023-02-01","conditions":"Hemophilia","enrollment":91},{"nctId":"NCT05802940","phase":"NA","title":"Low Dose Aspirin Alerts in High-Risk Pregnancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Geisinger Clinic","startDate":"2023-06-19","conditions":"Preeclampsia, Aspirin, Clinical Decision Support Systems","enrollment":839},{"nctId":"NCT06145373","phase":"PHASE4","title":"A Study to Test a Medicine (Fitusiran) for Preventing Bleeds in People With Severe Hemophilia Who Previously Received Preventive Treatment With Emicizumab","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-03-01","conditions":"Hemophilia A","enrollment":20},{"nctId":"NCT07141901","phase":"NA","title":"Life Expectancy-informed Colorectal Cancer Screening","status":"NOT_YET_RECRUITING","sponsor":"Kathryn Martinez","startDate":"2026-08-01","conditions":"Colorectal Cancer Control and Prevention","enrollment":15000},{"nctId":"NCT07115966","phase":"NA","title":"Impact of a Simple Automated Best Practice Alert (BPA) on Quantity and Quality of In-hospital Antibiotic Use in a Tertiary and Three Secondary Hospitals","status":"ACTIVE_NOT_RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2025-08-01","conditions":"Antibiotic Prescriptions, In-Patient Treatment","enrollment":58},{"nctId":"NCT05341986","phase":"NA","title":"Optimizing Stroke Prophylaxis of Acute Atrial Fibrillation With an Electronic Clinical Decision Support Tool","status":"ENROLLING_BY_INVITATION","sponsor":"Oregon Health and Science University","startDate":"2022-01-11","conditions":"Atrial Fibrillation","enrollment":36},{"nctId":"NCT03549871","phase":"PHASE3","title":"A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-07-25","conditions":"Hemophilia","enrollment":80},{"nctId":"NCT03417102","phase":"PHASE3","title":"A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2018-02-14","conditions":"Hemophilia A, Hemophilia B","enrollment":60},{"nctId":"NCT01893879","phase":"NA","title":"Placebo-Controlled Therapeutic Trial for the Prevention of Lymphedema","status":"TERMINATED","sponsor":"Stanford University","startDate":"2014-04","conditions":"Lymphedema, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":14}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"BPA prophylaxis","genericName":"BPA prophylaxis","companyName":"Genzyme, a Sanofi Company","companyId":"genzyme-a-sanofi-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BPA prophylaxis prevents breakthrough polyomavirus-associated nephropathy (BPA) in immunocompromised patients, likely through antiviral or immunomodulatory mechanisms. Used for Prophylaxis of breakthrough polyomavirus-associated nephropathy in immunocompromised patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}